Figure 2: Analysis of the validation cohort. The reactivity of CSF with OCBs from a second cohort of patients against myelin and non-myelin membranes was assessed using the ECL-based assay system. CSF from MS patients with OCB revealed higher reactivity against myelin as compared with ONDs with OCBs. When reactivity against myelin and non-myelin membrane was compared, CSF from these MS patients showed higher reactivity to myelin, while CSF from OND with OCB exhibited higher reactivity against the nonmyelin fraction. CIS OCB+ did not show any difference in reactivity against myelin as compared with the non-myelin membrane fraction (*p < 0.05, **p < 0.01, ***p < 0.001; two-way ANOVA).